*Non-GCs Drug-Induced Osteoporosis DOI: http://dx.doi.org/10.5772/intechopen.108296*

letrozole and exemestane on bone mass and bone turnover. Breast Cancer Research and Treatment. 2015;**154**(2):263-273. DOI: 10.1007/ s10549-015-3608-8 PMID 26536870

[26] Rodríguez-Sanz M, García-Giralt N, Prieto-Alhambra D, Servitja S, Balcells S, Pecorelli R, et al. CYP11A1 expression in bone is associated with aromatase inhibitor-related bone loss. Journal of Molecular Endocrinology. 2015;**55**(1):69- 79. DOI: 10.1530/JME-15-0079 PMID 26108486

[27] Liu M, Goss PE, Ingle JN, Kubo M, Furukawa Y, Batzler A, et al. Aromatase inhibitor-associated bone fractures: A case-cohort GWAS and functional genomics. Molecular Endocrinology. 2014;**28**(10):1740-1751. DOI: 10.1210/ me.2014-1147 PMID 25148458

[28] Wang J, Lu K, Song Y, Zhao S, Ma W, Xuan Q et al. RANKL and OPG polymorphisms are associated with aromatase inhibitor-related musculoskeletal adverse events in Chinese Han breast cancer patients. PLoS One. 2015;**10**(7):e0133964. DOI: 10.1371/ journal.pone.0133964, PMID 26218592

[29] May KP, West SG, Mcdermott MT, Huffer WE. The effect of low dose methotrexate on bone metabolism and histomorphometry in rats. Arthritis and Rheumatism. 1994;**37**(2):201-206. DOI: 10.1002/art.1780370208 PMID 8129775

[30] Preston SJ, Diamond T, Scott A, Laurent MR. Methotrexate osteopathy in rheumatic disease. Annals of the Rheumatic Diseases. 1993;**52**(8):582-585. DOI: 10.1136/ard.52.8.582 PMID 8215620

[31] Wang D, Christensen K, Chawla K, Xiao G, Krebsbach PH, Franceschi RT. Isolation and characterization of MC3T3-E1 preosteoblast subclones with distinct in vitro and in vivo differentiation/

mineralization potential. Journal of Bone and Mineral Research. 1999;**14**(6):893- 903. DOI: 10.1359/jbmr.1999.14.6.893 PMID 10352097

[32] Wang D, Christensen K, Chawla K, Xiao G, Krebsbach PH, Franceschi RT. Isolation and characterization of MC3T3-E1 preosteoblast subclones with distinct in vitro and in vivo differentiation/ mineralization potential. Journal of Bone and Mineral Research. 1999;**14**(6):893- 903. DOI: 10.1359/jbmr.1999.14.6.893, PMID 10352097

[33] May KP, Mercill D, Mcdermott MT, West SG. The effect of methotrexate on mouse bone cells in culture. Arthritis and Rheumatism. 1996;**39**(3):489-494. DOI: 10.1002/art.1780390317 PMID 8607898

[34] Zonneveld IM, Bakker WK, Dijkstra PF, Bos JD, van Soesbergen RM, Dinant HJ. Methotrexate osteopathy in long-term, low-dose methotrexate treatment for psoriasis and rheumatoid arthritis. Archives of Dermatology. 1996;**132**(2):184-187 PMID 8629827.

[35] Ott C, Schölmerich J. Extraintestinal manifestations and complications in IBD. Nature Reviews. Gastroenterology & Hepatology. 2013;**10**(10):585-595. DOI: 10.1038/nrgastro.2013.117 PMID 23835489 [PMID 23835489]

[36] Miheller P, Gesztes W, Lakatos PL. Manipulating bone disease in inflammatory bowel disease patients. Annals of Gastroenterology. 2013;**26**(4):296-303 PMID 24714303

[37] Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World Journal of Gastroenterology. 2006;**12**(30):4819-4831. DOI: 10.3748/ wjg.v12.i30.4819 PMID 16937463

[38] Ali T, Lam D, Bronze MS, Humphrey MB. Osteoporosis in inflammatory bowel disease. The American Journal of Medicine. 2009;**122**(7):599-604. DOI: 10.1016/j. amjmed.2009.01.022 PMID 19559158 [PMID19559158]

[39] Targownik LE, Bernstein CN, Leslie WD. Inflammatory bowel disease and the risk of osteoporosis and fracture. Maturitas. 2013;**76**(4):315-319. DOI: 10.1016/j.maturitas.2013.09.009 PMID 24139749 [PMID 24139749]

[40] Miheller P, Lorinczy K, Lakatos PL. Clinical relevance of changes in bone metabolism in inflammatory bowel disease. World Journal of Gastroenterology. 2010;**16**:5536-5542 [PMID 21105186, p. i44.5536]. DOI: 10.3748/wjg

[41] Bernstein CN, Blanchard JF, Leslie W, Wajda A, Yu BN. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Annals of Internal Medicine. 2000;**133**(10):795- 799. DOI: 10.7326/0003-4819-133-10- 200011210-00012 PMID 11085842 [PMID 11085842]

[42] Schoon EJ, Blok BM, Geerling BJ, Russel MG, Stockbrügger RW, Brummer RJ. Bone mineral density in patients with recently diagnosed inflammatory bowel disease. Gastroenterology. 2000;**119**(5):1203- 1208. DOI: 10.1053/gast.2000.19280 PMID 11054377 [PMID 11054377]

[43] Sakellariou GT, Moschos J, Berberidis C, Mpoumponaris A, Kadis S, Molyvas E, et al. Bone density in young males with recently diagnosed inflammatory bowel disease. Joint, Bone, Spine. 2006;**73**(6):725-728. DOI: 10.1016/j.jbspin.2006.01.017 PMID 17126059 [PMID 17126059]

[44] Reinshagen M. Osteoporosis in inflammatory bowel disease. Journal of Crohn's & Colitis. 2008;**2**:202-207 [PMID 21172211]. DOI: 10.1016/j. crohns.2008.01.005

[45] Mundy GR. Osteoporosis and inflammation. Nutrition Reviews. 2007;**65**(12 Pt 2):S147-S151. DOI: 10.1111/j.1753-4887.2007.tb00353.x PMID 18240539 [PMID 18240539]

[46] Redlich K, Smolen JS. Inflammatory bone loss: Pathogenesis and therapeutic intervention. Nature Reviews. Drug Discovery. 2012;**11**(3):234-250. DOI: 10.1038/nrd3669 PMID 22378270 [PMID 22378270]

[47] Reffitt DM, Meenan J, Sanderson JD, Jugdaohsingh R, Powell JJ, Thompson RP. Bone density improves with disease remission in patients with inflammatory bowel disease. European Journal of Gastroenterology & Hepatology. 2003;**15**(12):1267-1273. DOI: 10.1097/ 00042737-200312000-00003 PMID 14624148 [PMID 14624148]

[48] Wong PK, Christie JJ, Wark JD. The effects of smoking on bone health. Clinical Science (London, England). 2007;**113**(5):233-241. DOI: 10.1042/ CS20060173 PMID 17663660 [PMID 17663660]

[49] Yoon V, Maalouf NM, Sakhaee K. The effects of smoking on bone metabolism. Osteoporosis International. 2012;**23**(8): 2081-2092. DOI: 10.1007/s00198-012- 1940-y PMID 22349964 [PMID 22349964]

[50] Cosnes J. Smoking, physical activity, nutrition and lifestyle: Environmental factors and their impact on IBD. Digestive Diseases. 2010;**28**(3):411-417. DOI: 10.1159/000320395 PMID 20926865 [PMID 20926865]

[51] Silvennoinen J, Lamberg-Allardt C, Kärkkäinen M, Niemelä S, Lehtola J.

*Non-GCs Drug-Induced Osteoporosis DOI: http://dx.doi.org/10.5772/intechopen.108296*

Dietary calcium intake and its relation to bone mineral density in patients with inflammatory bowel disease. Journal of Internal Medicine. 1996;**240**(5):285-292. DOI: 10.1046/j.1365-2796.1996. 25862000.x PMID 8946811

[52] Cashman KD, Shanahan F. Is nutrition an aetiological factor for inflammatory bowel disease? European Journal of Gastroenterology & Hepatology. 2003;**15**(6):607-613. DOI: 10.1097/00042737-200306000-00005 PMID 12840670

[53] McCarthy D, Duggan P, O'Brien M, Kiely M, McCarthy J, Shanahan F, et al. Seasonality of vitamin D status and bone turnover in patients with Crohn's disease. Alimentary Pharmacology & Therapeutics. 2005;**21**(9):1073-1083. DOI: 10.1111/j.1365-2036.2005.02446.x PMID 15854168

[54] Gilman J, Shanahan F, Cashman KD. Determinants of vitamin D status in adult Crohn's disease patients, with particular emphasis on supplemental vitamin D use. European Journal of Clinical Nutrition. 2006;**60**(7):889-896. DOI: 10.1038/ sj.ejcn.1602395 PMID 16493452

[55] Mouli VP, Ananthakrishnan AN. Review article: Vitamin D and inflammatory bowel diseases. Alimentary Pharmacology & Therapeutics. 2014;**39**(2):125-136. DOI: 10.1111/apt.12553 PMID 24236989 [PMID 24236989]

[56] Duggan P, O'Brien M, Kiely M, McCarthy J, Shanahan F, Cashman KD. Vitamin K status in patients with Crohn's disease and relationship to bone turnover. The American Journal of Gastroenterology. 2004;**99**(11):2178- 2185. DOI: 10.1111/j.1572-0241.2004. 40071.x PMID 15555000

[57] Dussault PM, Lazzari AA. Epilepsy and osteoporosis risk. Current Opinion in Endocrinology, Diabetes, and Obesity. 2017;**24**(6):395-401. DOI: 10.1097/ MED.0000000000000366 PMID 28857845

[58] Shiek Ahmad B, Hill KD, O'Brien TJ, Gorelik A, Habib N, Wark JD. Falls and fractures in patients chronically treated with antiepileptic drugs. Neurology. 2012;**79**(2):145-151. DOI: 10.1212/ WNL.0b013e31825f0466 PMID 22700806

[59] Samaniego EA, Sheth RD. Bone consequences of epilepsy and antiepileptic medications. Seminars in Pediatric Neurology. 2007;**14**(4):196-200. DOI: 10.1016/j.spen.2007.08.006 PMID 18070676

[60] Beerhorst K, Tan IY, De Krom M, Verschuure P, Aldenkamp AP. Antiepileptic drugs and high prevalence of low bone mineral density in a group of inpatients with chronic epilepsy. Acta Neurologica Scandinavica. 2013;**128**(4):273-280. DOI: 10.1111/ ane.12118 PMID 23461582

[61] Vestergaard P, Tigaran S, Rejnmark L, Tigaran C, Dam M, Mosekilde L. Fracture risk is increased in epilepsy. Acta Neurologica Scandinavica. 1999;**99**(5):269-275. DOI: 10.1111/j.1600- 0404.1999.tb00675.x PMID 10348155

[62] Vestergaard P. Epilepsy, osteoporosis and fracture risk - a meta-analysis. Acta Neurologica Scandinavica. 2005;**112**(5):277-286. DOI: 10.1111/j. 1600-0404.2005.00474.x PMID 16218908

[63] Desai KB, Ribbans WJ, Taylor GJ. Incidence of five common fracture types in an institutional epileptic population. Injury. 1996;**27**(2):97-100. DOI: 10.1016/ 0020-1383(95)00189-1 PMID 8730381

[64] Jetté N, Lix LM, Metge CJ, Prior HJ, McChesney J, Leslie WD. Association of antiepileptic drugs with nontraumatic fractures: A population-based analysis. Archives of Neurology. 2011;**68**(1):107- 112. DOI: 10.1001/archneurol.2010.341 PMID 21220681

[65] Miziak B, Chrościńska-Krawczyk M, Czuczwar SJ. An update on the problem of osteoporosis in people with epilepsy taking antiepileptic drugs. Expert Opinion on Drug Safety. 2019;**18**(8):679- 689. DOI: 10.1080/14740338.2019.1625887 PMID 31159612

[66] Dent CE, Richens A, Rowe DJ, Stamp TC. Osteomalacia with long-term anticonvulsant therapy in epilepsy. British Medical Journal. 1970;**4**(5727):69-72. DOI: 10.1136/bmj.4.5727.69 PMID 5312062

[67] Svalheim S, Sveberg L, Mochol M, Taubøll E. Interactions between antiepileptic drugs and hormones. Seizure. 2015;**28**:12-17. DOI: 10.1016/j. seizure.2015.02.022 PMID 25797888

[68] Krishnamoorthy G, Nair R, Sundar U, Kini P, Shrivastava M. Early predisposition to osteomalacia in Indian adults on phenytoin or valproate monotherapy and effective prophylaxis by simultaneous supplementation with calcium and 25-hydroxy vitamin D at recommended daily allowance dosage: A prospective study. Neurology India. 2010;**58**(2):213-219. DOI: 10.4103/0028- 3886.63796 PMID 20508338

[69] Hahn TJ, Halstead LR. Anticonvulsant drug-induced osteomalacia: Alterations in mineral metabolism and response tovitamin D3 administration. Calcified Tissue International. 1979;**27**(1):13-18. DOI: 10.1007/BF02441155 PMID 223750

[70] Tjellesen L, Nilas L, Christiansen C. Does carbamazepine cause disturbances in calcium metabolism in epileptic patients? Acta Neurologica Scandinavica. 1983;**68**(1):13-19. DOI: 10.1111/j.1600- 0404.1983.tb04809.x PMID 6613523

[71] Kwasa JK, Amayo A, Ndavi PM, Kwasa TO. Bone metabolism in healthy ambulatory control premenopausal women and in epileptics on anticonvulsant drugs. East African Medical Journal. 2010;**87**(4):151-155. DOI: 10.4314/ eamj.v87i4.62411 PMID 23057290

[72] Ashjazadeh N, Zamani A, Pourjafar M, Omrani GR. Bone density of ambulatory adult patients receiving long-term anticonvulsant drug therapy. Archives of Iranian Medicine. 2009;**12**(6):550-554 PMID 19877746

[73] Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. Journal of the American Medical Association. 2003;**290**(2):199-206. DOI: 10.1001/ jama.290.2.199 PMID 12851274

[74] Kanis JA, on behalf of the World Health Organization Scientific Group (2007). Assessment of osteoporosis at the primary health-care level. In: Technical Report. World Health Organization Collaborating Centre for Metabolic Bone Diseases. UK: University of Sheffield; 2007

[75] Yang S, Nguyen ND, Center JR, Eisman JA, Nguyen TV. Association between hypertension and fragility fracture: A longitudinal study. Osteoporosis International. 2014;**25**(1):97-103. DOI: 10.1007/s00198- 013-2457-8 PMID 23892585

[76] Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, et al. Risk factors for hip fracture in white women. Study of osteoporotic fractures research group. The New England Journal of Medicine. 1995;**332**(12):767-773. DOI: 10.1056/ NEJM199503233321202 PMID 7862179
